Pharmaceuticals
CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting
* CS1001-201 study demonstrated an objective response rate (ORR) of 44.7%, a complete response (CR) rate of 31.6%, median overall survival (mOS) of 19.7 months and an one-year overall survival (OS) rate of 55.5% in patients with relapsed or refractory extranodal natural killer /T cell lymphoma ...
2020-09-25 15:28
4221
CStone Announces Preliminary Results from a Bridging Study of Avapritinib in Chinese Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors at the 2020 CSCO Annual Meeting
* Avapritinib has demonstrated strong anti-tumor activity in Chinese patients with PDGFRA D842V mutant GIST * Avapritinib was generally well tolerated in Chinese GIST patients, consistent with the safety profile demonstrated in global studies SUZHOU, China, Sept. 25, 2020 /PRNewswire/ -- CSton...
2020-09-25 14:53
4364
GenScript ProBio Congratulates XLifeSc on FDA Allowance of IND Application for TCR-T Program
NANJING, China, Sept. 24, 2020 /PRNewswire/ -- On September 24, XiangXue Life Sciences (XLifeSc), a partner of GenScript ProBio, announces FDA allowance of its IND application for TCR-T program (TCRT-ESO-A2). GenScript ProBio extends congratulations on this. This program is China's first TCR-T...
2020-09-24 22:00
2044
New Centre for Medicines Research Report from Clarivate Indicates Drug Development Timelines are Shortest Since 2013
Pharmaceutical R&D industry report provides insights into what's behind decline in global NME outputs and reveals implications of decreased projected expenditures LONDON, Sept. 24, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to acc...
2020-09-24 16:15
8937
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
INCHEON, South Korea, Sept. 23, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According to Kanaph Therapeutics, KNP-301 is designed to ta...
2020-09-24 08:00
1515
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital
SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...
2020-09-24 00:09
2178
Insilico releases Pandomics, AI-powered platform for Novel Therapeutic Target Discovery
A novel end-to-end AI-hypothesis generation engine that seamlessly interprets OMICS and text-based data for the discovery and analysis of novel therapeutic targets HONG KONG, Sept. 23, 2020 /PRNewswire/ -- Insilico Medicine announces the official release ofPandomics - a part of the Pharma.ai AI ...
2020-09-23 22:00
3105
Genor Biopharma Announces Proposed Listing on the Main Board of SEHK
HONG KONG, Sept. 23, 2020 /PRNewswire/ -- JHBP (CY) Holdings Limited ("Genor Biopharma"or the "Company"; stock code: 6998.HK), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, announced the proposed listing of its shares on the...
2020-09-23 12:00
3121
Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial
BAGSVAERD, Denmark, Sept. 22, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual ...
2020-09-22 20:53
3000
New Study Suggests GlycoMark® May Identify Highest Risk Patients with Prediabetes
RALEIGH, North Carolina, Sept. 22, 2020 /PRNewswire/ -- According to new data presented at the 56th European Association for the Study of Diabetes (EASD) annual meeting, the GlycoMark blood test reflects beta-cell functional mass, which is important in identifying prediabetic individuals with the...
2020-09-22 19:00
1850
TCM Lianhua Qingwen Capsule approved for registration in Mauritius
SHIJIAZHUANG, China, Sept. 22, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. (SHE: 002603) announced on Tuesday that it has received a registration approval issued by the Ministry of Health and Wellness ofMauritius, indicating Lianhua Qingwen Capsule has been registered in accordance with ...
2020-09-22 15:21
1905
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administr...
2020-09-21 20:12
3997
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
SHANGHAI and GAITHERSBURG, Md., Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...
2020-09-21 20:00
5937
PharmAbcine expands partnership with Samsung Biologics for PMC-403
DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...
2020-09-21 20:00
1725
Hyde Engineering + Consulting Announces New VP of Global Engineering
BOULDER, Colorado, Sept. 21, 2020 /PRNewswire/ -- Hyde Engineering + Consulting, Inc. (Hyde) announced thatSanjay Shah has accepted the position of Vice President of Global Engineering. Sanjay, based out of Hyde's office in Ahmedabad,India, will provide subject matter expertise in conceptual an...
2020-09-21 11:30
3242
Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain
SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or "Company") announced that, the clinical trial in patients with peripheral neuropathic pain has been initiated for the candidate drug SR419, and the first patient has been successfu...
2020-09-21 10:35
2843
Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020
SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...
2020-09-21 08:00
7653
Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020
SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...
2020-09-21 08:00
6665
Preparation products of Yiling Pharma approved by FDA for launch in the US market
SHIJIAZHUANG, China, Sept. 19, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter ...
2020-09-19 19:14
2749
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
Not intended for US-, Canada- and UK-based media DARMSTADT, Germany, and NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print inThe New England Journal of...
2020-09-18 15:00
10283
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
